Background: Programmed death 1 (PD-1) and CTLA-4 blockade demonstrated durable clinical benefit in patients with advanced mismatch repair deficient (dMMR) colorectal cancer. This is the first neoadjuvant study to test ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD1) in early stage dMMR and MMR proficient (pMMR) colon cancers (CC). Methods: Patients with resectable, early stage CC received ipilimumab 1mg/kg on day (D)1 and nivolumab 3mg/kg on D1 þ 15. Surgery was planned a maximum of 6 weeks after informed consent. Primary endpoints were safety and feasibility. Secondary endpoints included: efficacy assessed by pathological response criteria, and associations between response and tumor mutational burden (TMB), interferon (IFN) c gene signatures, T-cell infiltration and T-cell receptor (TCR) clonality. Results: So far, 14 patients with either pMMR (n ¼ 8) or dMMR (n ¼ 7) tumors were treated. Treatment was well-tolerated and all patients underwent radical resection of 15 tumors without delays in surgery. Major pathological responses (<5% viable tumor cells) were observed in 7/7 (100%) dMMR CC, with 4/7 (57%) complete responses. Four of these dMMR tumors were clinically stage IIIB/C before start of treatment. Even though no major pathological responses were seen in pMMR tumors, significant increases in T-cell infiltration, particularly CD8þ T-cells, were seen post-treatment in both pMMR and dMMR tumors, with a median fold change of 2.4 (p ¼ 0.018) and 4.8 (p ¼ 0.0009), respectively. Strikingly, in spite of the major difference in TMB between dMMR and pMMR tumors (p ¼ 0.008), pre-treatment TCR clonality and IFN c gene signatures did not differ substantially between these tumors. In contrast, post-treatment IFN c signatures increased the ability to distinguish responders (dMMR) from non-responders (pMMR). Conclusions: Short-term, neoadjuvant ipilimumab plus nivolumab resulted in major pathological responses in 100% of dMMR tumors and did not compromise surgery. While dMMR status and TMB were associated with response, pre-treatment measures of tumor inflammation may have limited predictive value. Our data suggest that neoadjuvant immunotherapy in dMMR CC warrants further research and has the potential to change the current standard of care. Clinical trial identification: NCT03026140. Legal entity responsible for the study: Netherlands Cancer Institute. Funding: Bristol-Myers Squibb. Disclosure: All authors have declared no conflicts of interest. Methods: These first-in-human dose-escalation studies use a modified 3 þ 3 design to evaluate safety. Patients (pts) are enrolled after receiving !1 line of therapy. Different cyclophosphamide/fludarabine lymphodepleting regimens are utilized based on dose group: group 1 target dose is 0.1 Â 10 9 transduced cells, group 2 is 1 Â 10 9 , and group 3 is 5 Â 10 9 . Cohort expansion will occur at the maximum tolerated dose. Dose-limiting toxicities (DLTs) are adjudicated by a Safety Review Committee (SRC). Results: As of 25 Jun 2018, 11 pts (7 male, median age 61 y) have been treated; 8 pts in group 1, 3 pts in group 2. AEs ! Grade 3 occurred in 9 pts; most frequently reported were lymphopenia (6), thrombocytopenia (5), anaemia (4), neutropenia (4), leukopenia (4), and hyponatremia (3). 7 pts reported serious AEs including: 2 CRS* (*¼related to T-cell therapy), 2 dyspnoea and 1 each of abdominal pain, disease progression, haemoptysis*, neutropenia, pneumonia, respiratory failure, sepsis and thrombocytopenia. One Grade 4 CRS in group 1, which resolved with tocilizumab and steroids, was considered a DLT. For the 8 pts in group 1, their disease progressed. In Group 2, 1 pt died of pneumonia (MRSA, unrelated to T-cell therapy). 1 pt had stable disease (SD) at wk 4 but then progressed at wk 8; 1 pt had SD at wk 8 but progressed at wk 12. Cytokine levels were within ranges observed in other SPEAR T-cell studies. SPEAR T-cells were detectable in peripheral blood in both groups. After evaluating NSCLC group 2 data, the SRC agreed that both trials should dose escalate. Conclusions: MAGE-A10 SPEAR T-cells at doses of 0.1 Â 10 9 and 1 Â 10 9 cells show no evidence of toxicity related to off-target binding or alloreactivity. Most AEs were consistent with those experienced by cancer patients undergoing chemotherapy or other immunotherapies. Enrolment in dose Group 3 (5 Â 10 9 cells and increased conditioning dosing) is ongoing. Clinical trial identification: NCT02592577, NCT02989064. Editorial acknowledgement: Editorial support will be provided by Envision Pharma. Legal entity responsible for the study: Adaptimmune. Funding: Adaptimmune. Disclosure: D.S. Hong: Research/grant funding: AbbVie, Adaptimmune, Amgen,
